| Size | Price | Stock | Qty |
|---|---|---|---|
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Latanoprost (PHXA-41, XA-34) is a novel prostaglandin F2α analogue that lowers the pressure by increasing the outflow of aqueous fluid from the eyes through the uvealsclearal tract. Latanoprost is an isopropyl ester prodrug, meaning it is inactive until it is hydrolyzed by esterases in the cornea to the biologically active acid. Latanoprost, in pure form, is an oily liquid. For the convenience of use, it is supplied as 200mg / mL in ethanol.
| ln Vitro |
considerable apoptosis was triggered in the top layer by benzoalkonium chloride-latanoprost (BAK-latanoprost) and 0.02% BAK, which was linked to a considerable reduction in cell viability. When compared to PBS, the moderate reduction in cell viability caused by Preservative-free latanoprost (PF-latanoprost) and the small number of apoptotic cells identified in the superficial layer did not reach statistical significance [1]. Comparing latanoprost (0.1 μM) to the control, cell viability rose considerably. Simultaneously, 0.1 μM latanoprost can strongly stimulate neurite formation in a manner akin to that of ciliary neurotrophic factor (CNTF) and raise p-Akt and p-mTOR expression levels. By controlling the FP receptor-mediated PI3K-Akt-mTOR signaling cascade, latanoprost can stimulate neurite growth [3]. Latanoprost (0.03 or 0.3 μg/mL) and bimatoprost (75% ± 27% and 75% ± 24%, respectively) enhanced MMP-9 activity in human CBSM cells [4].
|
|---|---|
| ln Vivo |
In beagle dogs, one drop of latanoprost results in significant miosis, peripheral iris lordosis, iridocorneal angle narrowing, and anterior chamber shallowing. Pupil diameter, ACA, and AOD (mean) decreased by 84%, 14%, and 16%, respectively, following the use of latanoprost [2].
|
| References |
[1]. Pauly A, et al. In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation. Invest Ophthalmol Vis Sci. 2012 Dec 13;53(13):8172-80.
[2]. Zheng J, et al. Latanoprost promotes neurite outgrowth in differentiated RGC-5 cells via the PI3K-Akt-mTOR signaling pathway. Cell Mol Neurobiol. 2011 May;31(4):597-604. [3]. Tsai S, et al. The effect of topical latanoprost on anterior segment anatomic relationships in normal dogs. Vet Ophthalmol. 2013 Sep;16(5):370-6. [4]. Ooi YH, et al. Effect of bimatoprost, latanoprost, and unoprostone on matrix metalloproteinases and their inhibitors in human ciliary body smooth muscle cells. Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5259-65. [5]. B'Ann True Gabelt, et al. Prostaglandin Subtype-Selective and Non-Selective IOP-Lowering Comparison in Monkeys |
| Molecular Formula |
C26H40O5
|
|---|---|
| Molecular Weight |
432.6
|
| CAS # |
130209-82-4
|
| Related CAS # |
Latanoprost-d4
|
| SMILES |
O=C(OC(C)C)CCC/C=C\C[C@@H]1[C@@H](CC[C@@H](O)CCC2=CC=CC=C2)[C@H](O)C[C@@H]1O
|
| InChi Key |
GGXICVAJURFBLW-CEYXHVGTSA-N
|
| InChi Code |
InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1
|
| Chemical Name |
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
|
| Synonyms |
PHXA41 PHXA-41 PHXA 41 XA34 XA-34 XA 34 Latanoprost, Xalatan, Catioprost
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~100 mg/mL (~231.17 mM)
Ethanol : ~100 mg/mL (~231.17 mM) DMSO : ≥ 100 mg/mL (~231.17 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.81 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 100 mg/mL (231.17 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3116 mL | 11.5580 mL | 23.1160 mL | |
| 5 mM | 0.4623 mL | 2.3116 mL | 4.6232 mL | |
| 10 mM | 0.2312 mL | 1.1558 mL | 2.3116 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA